Home Cart Sign in  
Chemical Structure| 1392136-43-4 Chemical Structure| 1392136-43-4

Structure of Verdinexor
CAS No.: 1392136-43-4

Chemical Structure| 1392136-43-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Verdinexor is an orally bioavailable selective inhibitor of nuclear export (SINE), inhibits nuclear export protein Exportin 1 (XPO1/CRM1) against canine tumor cell lines and also reduce influenza virus replication in vitro and in vivo.

Synonyms: KPT-335; ATG-527

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Verdinexor

CAS No. :1392136-43-4
Formula : C18H12F6N6O
M.W : 442.32
SMILES Code : O=C(NNC1=NC=CC=C1)/C=C\N2N=C(C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)N=C2
Synonyms :
KPT-335; ATG-527
MDL No. :MFCD28167840
InChI Key :OPAKEJZFFCECPN-XQRVVYSFSA-N
Pubchem ID :71492799

Safety of Verdinexor

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Description
Verdinexor (KPT-335) is an innovative, orally-administered selective inhibitor of nuclear export (SINE) that blocks the nuclear export protein Exportin 1 (XPO1/CRM1), showing efficacy against canine cancer cell lines[1].
Target
  • CRM1

In Vitro:

Cell Line
Concentration Treated Time Description References
KYSE510 20 μM 48 hours To evaluate the inhibitory effect of Verdinexor on the proliferation of esophageal cancer cells PMC8692140
KYSE180 20 μM 48 hours To evaluate the inhibitory effect of Verdinexor on the proliferation of esophageal cancer cells PMC8692140
KYSE450 20 μM 48 hours To evaluate the inhibitory effect of Verdinexor on the proliferation of esophageal cancer cells PMC8692140
KYSE30 20 μM 48 hours To evaluate the independent cytotoxic effect of AZD1775 on esophageal cancer cell lines. AZD1775 (100 nM) as monotherapy did not alter the viability of ESCA cells, but significantly radiosensitized ESCA cells. PMC8692140
SH-SY5Y 0.3 µM 48 hours To evaluate the inhibitory effect of Verdinexor on neuroblastoma cell proliferation. Results showed that Verdinexor significantly inhibited the proliferation of SH-SY5Y cells and induced apoptosis. PMC8359549
SK-N-BE(2) 1.4 µM 48 hours To investigate the effect of ATR inhibition on RA-induced differentiation of neuroblastoma cells, results showed low-dose elimusertib significantly enhanced RA-induced neuronal differentiation. PMC8359549
Bone marrow mononuclear cells (BMMC) 0.01 μM, 0.05 μM, 0.1 μM, 0.5 μM, 1 μM, 10 μM 24 hours-4 days To evaluate the effect of Verdinexor on the survival of plasma cells in bone marrow and blood. Results showed that bone marrow-derived plasma cells were less sensitive to Verdinexor compared to those from blood. PMC11757124
293T cells 1 μM 6 hours PMC4136318
MDCK cells 1 μM 2 hours Evaluate the inhibitory effect of GA-A on cyst growth in MDCK cells, showing significant inhibition without cytotoxicity. PMC4136318
A549 cells 1 μM 2 hours Inhibited RSK4 activation, resulting in decreased cellular cIAP1 and cIAP2 expression PMC4136318
BEAS-2B cells 1 μM 24 hours To evaluate the effects of Licochalcone A on oxidative responses and inflammatory cytokine levels. Licochalcone A significantly inhibited reactive oxygen species, eotaxin, and proinflammatory cytokines in BEAS-2B cells. PMC6364025
VeroE6 cells 0.1 µM 4 days To evaluate the inhibitory effect of Verdinexor on SARS-CoV-2 replication, results showed that 0.1 µM Verdinexor reduced viral replication by approximately 15%. PMC9168989
Mouse embryonic fibroblasts (MEFs) 2.5μM 2 hours PMC5130180
Vero cells 2.5μM 2 hours PMC5130180
A549 cells 0.2μM 2 hours Inhibited RSK4 activation, resulting in decreased cellular cIAP1 and cIAP2 expression PMC5125695

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice KYSE30 xenograft model 5 mg/kg Intraperitoneal injection 24 days To evaluate the inhibitory effect of Verdinexor on tumor growth of esophageal cancer in vivo PMC8692140
Nude mice Neuroblastoma xenograft model 10 mg/kg Oral gavage Three times per week for four weeks To evaluate the antitumor effects of Verdinexor in vivo. Results showed that Verdinexor significantly inhibited tumor growth without causing obvious toxic effects. PMC8359549
BALB/c mice Influenza virus infection model 10 or 20 mg/kg Oral Once daily for 3 days To evaluate the antiviral effect of Verdinexor in vivo, results showed that Verdinexor reduced lung viral loads, decreased inflammatory responses, and improved survival rates PMC4136318
Adult Sprague-Dawley rats Controlled cortical impact (CCI) model of TBI 5 mg/kg or 7 mg/kg oral Starting at 2 h post-TBI and once a day thereafter over the next 4 days To evaluate the effects of SINE compounds on TBI-induced behavioral and histological deficits. Results showed that rats treated with KPT-350 exhibited significantly better motor coordination and balance in the rotorod test and motor asymmetry test, with improvements of 100–200%, observed as early as 4 h after initial SINE compound injection and sustained throughout the 18-day post-TBI study period (P<0.05). Additionally, KPT-350 reduced cortical core impact area and peri-impact cell death (P<0.05). PMC5067638
Mice Influenza virus infection model 20 mg/kg Oral Once on day 1 and day 3 post-infection To evaluate the inhibitory effect of Verdinexor on influenza virus replication in vivo, results showed that Verdinexor significantly reduced virus shedding and pulmonary inflammatory response PMC5125695

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.26mL

0.45mL

0.23mL

11.30mL

2.26mL

1.13mL

22.61mL

4.52mL

2.26mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories